Across the world, the use of bilateral trade instruments to prise open markets for genetically modified (GM) crops is escalating. To expand business overseas, the biotech industry needs stronger intellectual property rules and weaker biosafety standards. Bilateral trade deals are an effective way to do this. This report looks specifically at how the world’s grain and oilseed traders, who account for the bulk of the world’s GM crop production and trade today, use bilateral trade channels to prevent countries from building strong biosafety regulatory environments.
Read more here.